The pharmaceutical industry faces numerous challenges in the development of novel compounds. Phase 2 clinical trial success rates are at a 5-year low of 22%, and the average number of preclinical drug development programs needed to produce a single new drug has increased from 12 to 30 between 2007 and 2012 alone.1 One estimate suggests that the average new drug requires more than $1.8 billion and 12 years from the time of discovery to commercial launch.2 If drug development is to remain commercially viable in the future, the current model for drugdiscovery and development must undergo a fundamental shift.
展开▼
